<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801253</url>
  </required_header>
  <id_info>
    <org_study_id>ID RCB: 2014-A01100-47</org_study_id>
    <nct_id>NCT02801253</nct_id>
  </id_info>
  <brief_title>Cohort of Prosthetic Joint Infections</brief_title>
  <acronym>COPINS</acronym>
  <official_title>Prospective Cohort of Patients With Prosthetic Joint Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Diaconesses Croix Saint-Simon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Diaconesses Croix Saint-Simon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Management of prosthetic joint infections (PJI) is a challenging task. These infections&#xD;
      include different clinical and microbiological settings calling upon various treatment&#xD;
      strategies according to infection type (acute or chronic), bone quality, the involved&#xD;
      micro-organism and the patient's general condition and willing.&#xD;
&#xD;
      Treatment of PJI combines surgery and prolonged antibiotic therapy. In some patients with a&#xD;
      high operative risk prolonged suppressive antibiotic therapy can be used.&#xD;
&#xD;
      Lack of large prospective studies motivated the conception of this cohort with a long term&#xD;
      follow up, regardless to PJI management procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large prospective cohort study in a French referral center for bone and joint infections.&#xD;
&#xD;
      Population&#xD;
&#xD;
        -  all patients who consented to participate in the study with PJI treated with:&#xD;
&#xD;
        -  debridement-synovectomy for acute infection&#xD;
&#xD;
        -  with one-stage, two-stage exchange arthroplasty for chronic infection&#xD;
&#xD;
        -  other procedures (complete removal of the prosthesis) and antibiotic therapy&#xD;
&#xD;
        -  patients (non-operated or operated) receiving prolonged suppressive antibiotic therapy&#xD;
&#xD;
      Outcome:&#xD;
&#xD;
        -  Follow-up at least 2 years&#xD;
&#xD;
        -  Events monitored: reinfection including relapse and new infection, joint revision for&#xD;
           mechanical failure, PJI related or non-related death Study duration: 10 years.&#xD;
           Recruitment period: 4 years. Maximal duration of data collection: 6 years. Investigator&#xD;
           center: monocenter study. Mean patient inclusion per year: 100 patients per year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2015</start_date>
  <completion_date type="Anticipated">September 2029</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hip and knee prosthetic joint reinfection (relapse and new infection) and multi-variable analysis of reinfection risk factors</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of joint function at one, two, four and 6 years after prosthesis revision with one or two stage exchange arthroplasty.</measure>
    <time_frame>1, 2, 4, 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of mechanical failure rate six years after prosthesis revision with one or two stage exchange arthroplasty</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of treatment failure rate in patients with hip and knee PJI 2 years after prolonged suppressive antibiotic therapy in non-operated patients.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of reinfection rate of shoulder PJI two years after prosthesis revision with one or two stage exchange arthroplasty.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients managed in the investigators referral center of bone and joint infection, who&#xD;
        meet protocol selection criteria will be included in the study. The investigators expect to&#xD;
        recruit 400 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged over 18 years old with hip, knee and or shoulder joint prosthesis who&#xD;
             consented to participate in the study with:&#xD;
&#xD;
          -  According to musculoskeletal infection society definition: PJI is present when one of&#xD;
             the major criteria exists or four out of six minor criteria.&#xD;
&#xD;
        Major Criteria:&#xD;
&#xD;
          -  Two positive periprosthetic cultures with phenotypically identical organisms, OR&#xD;
&#xD;
          -  A sinus tract communicating with the joint, OR&#xD;
&#xD;
        Minor Criteria:&#xD;
&#xD;
          -  Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)&#xD;
&#xD;
          -  Elevated synovial fluid white blood cell (WBC)&#xD;
&#xD;
          -  Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)&#xD;
&#xD;
          -  The presence of pus in the joint without known cause&#xD;
&#xD;
          -  Positive histological analysis of periprosthetic tissue&#xD;
&#xD;
          -  A single positive culture&#xD;
&#xD;
        Or a PJI which meets the following three criteria:&#xD;
&#xD;
          -  Medical story suggesting prosthetic joint infection.&#xD;
&#xD;
          -  The presence of pain either with or without swelling for more than 3 months unrelated&#xD;
             to a mechanical cause.&#xD;
&#xD;
          -  Germ identification in a single sample of fluid aspiration or tissue culture.&#xD;
&#xD;
               -  Or microbial growth in prosthesis sonication fluid culture greater than 50CFU/ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who does not meet eligibility criteria.&#xD;
&#xD;
          -  Patient lawfully deprived of his liberty.&#xD;
&#xD;
          -  Patient not insured under social security scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>VALERIE ZELLER, Doctorate</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YOUNES KERROUMI, Doctorate</last_name>
    <phone>(+33) 1 64 44 33 84</phone>
    <email>ykerroumi@hopital-dcss.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses Croix Saint Simon</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Younes KERROUMI, Doctorate</last_name>
      <phone>(+33)1 44 64 33 84</phone>
      <email>ykerroumi@hopital-dcss.org</email>
    </contact>
    <contact_backup>
      <last_name>Val√©rie ZELLER, Doctorate</last_name>
      <phone>(+33)1 44 64 17 80</phone>
      <email>vzeller@hopital-dcss.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Diaconesses Croix Saint-Simon</investigator_affiliation>
    <investigator_full_name>Dr Valerie ZELLER</investigator_full_name>
    <investigator_title>infectious diseases specialist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

